Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae139 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Gustavo C Penna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of Adult and Pediatric Endocrinology, Diabetes & Metabolism, The University of Chicago, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Thyroxine, Homeostasis, Hypothyroidism. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Brazilian Ministry of Health, NIDDK NIH HHS, University of Chicago.
Abstract (Originalsprache)
Context
The effectiveness of levothyroxine (LT4) in restoring thyroid hormone (TH) homeostasis, particularly serum thyroxine (T4) and triiodothyronine (T3) levels, remains debatable.
Objective
This work aimed to assess TH homeostasis in LT4-treated individuals using data from the Longitudinal Study of Adult Health in Brazil (ELSA-Brasil) study.
Methods
The ELSA-Brasil study follows 15 105 adult Brazilians (aged 35-74 years) over 8.2 years (2008-2019) with 3 observation points assessing health parameters including serum thyrotropin (TSH), free T4 (FT4), and free T3 (FT3) levels. We analyzed 186 participants that initiated treatment with LT4 during the study, and 243 individuals continuously treated with LT4 therapy.
Results
Initiation of therapy with LT4 resulted in an 11% to 19% decrease in TSH, an approximately 19% increase in FT4, and a 7% reduction in FT3 serum levels (FT3 dropped >10% in ∼40% of the LT4-treated patients). This was associated with an increase in triglyceride levels and utilization of hypolipidemic and antidiabetic medications. Participants continuously treated with LT4 exhibited a stable elevation in serum FT4 and a reduction in serum FT3 and TSH levels. While 115 participants (47.3%) had at least 1 serum FT4 levels above the control reference range (>1.52 ng/dL), 38 participants (15.6%) had at least 1 serum FT3 below the reference range (<0.23 ng/dL).
Conclusion
The present results challenge the dogma that treatment with LT4 for hypothyroidism restores TH homeostasis in all patients. A substantial number of LT4-treated patients exhibit repeated FT4 and FT3 levels outside the normal reference range, despite normal TSH levels. Further studies are needed to define the clinical implications of these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Adult and Pediatric Endocrinology, Diabetes & Metabolism, The University of Chicago, Chicago, IL 60637, USA.
- Department of Internal Medicine, Universidade Federal e Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
- Center for Clinical and Epidemiological Research, Hospital Universitário, Universidade de São Paulo, São Paulo, 05508-220, Brazil.
ORCID-Profile: Gustavo C Penna, Antonio C Bianco, Matthew D Ettleson
Förderung
- Brazilian Ministry of Health
- NIDDK NIH HHS
- University of Chicago
- Brazilian National Research Council
- Diabetes Research and Training Center
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Penna, G. C., Bensenor, I. M., Bianco, A. C., & Ettleson, M. D. (2024). Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae139
Vancouver
Penna GC, Bensenor IM, Bianco AC, Ettleson MD. Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae139
BibTeX
@article{Penna2024,
author = {Penna, Gustavo C and Bensenor, Isabela M and Bianco, Antonio C and Ettleson, Matthew D},
title = {Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae139}
}
EUVIMED